Biography
Emily Bergsland, MD is a medical oncologist at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center who specializes in gastrointestinal malignancies. She is a Professor of Medicine, Director of the UCSF Center for Neuroendocrine Tumors, and serves as Associate Director for Education for the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Bergsland leads a clinical-translational research program focused on neuroendocrine neoplasms of all grades, which includes clinical trials and collaborative studies related to biomarkers, imaging and clinical outcomes. She is past president of the North American Neuroendocrine Tumor Society, a longstanding member of the NCCN Neuroendocrine Tumor Guidelines panel, and past chair of the NET Task Force of the NCI Gastrointestinal Steering Committee.
Education
Institution | Degree | Dept or School | End Date |
---|---|---|---|
University of California | Diversity, Equity, and Inclusion Champion Training | 2019 | |
University of California (UCSF) | Molecular Medicine Training Program | 06/1998 | |
University of California (UCSF) | Fellowship | Medical Oncology | 06/1995 |
University of California (UCSF) | Chief Residency | 06/1993 | |
University of California (UCSF) | Residency | Internal Medicine | 06/1992 |
University of Minnesota | MD | Medicine | 06/1989 |
University of Wisconsin | BS | Biochemistry/Molecular Biology | 05/1985 |
Board Certifications
American Board of Internal Medicine
American Board of Internal Medicine: Medical Oncology - Subspecialty
Clinical Expertise
Colon Cancer
Esophageal Cancer
Liver Cancer
Lynch Syndrome
Pancreatic Cancer
Rectal Cancer
Stomach Cancer
Clinical Trials
- Related Conditions: Neuroendocrine Tumor, Neuroendocrine Carcinoma, Carcinoma| Start Date: | End Date:
- Related Conditions: Pancreatic Neuroendocrine Neoplasm, Neoplasms, Neuroendocrine Tumor| Start Date: | End Date:
- Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas (NCT03136055)Related Conditions: Neuroendocrine Carcinoma, Carcinoma| Start Date: | End Date:
- Related Conditions: Neuroendocrine Tumor, Carcinoid Tumor, Neoplasms, Pancreatic Cancer, Pancreatic Neoplasms, Stomach Cancer, Gastrointestinal Cancer| Start Date: | End Date:
- Related Conditions: Neuroendocrine Tumor| Start Date: | End Date:
- Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors (NCT00390156)Related Conditions: Solid Tumor, Neoplasms| Start Date: | End Date:
- Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors (NCT00227617)Related Conditions: Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor, Neoplasms, Gastrointestinal Cancer| Start Date: | End Date:
Grants and Funding
- UCSF Paul Calabresi K12 Career Development Program in Clinical Oncology | NIH | 2021-07-01 - 2026-06-30 | Role: Principal Investigator
Research Interests
Angiogenesis Inhibitors
Pancreatic Neoplasms
Vascular Endothelial Growth Factor
Colorectal Neoplasms
Neuroendocrine Tumors
Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 147
- Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center.| | View in PubMed
- The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy.| | View in PubMed
- Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors.| | View in PubMed
- The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study.| | View in PubMed
- Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.| | View in PubMed
- The Careers and Professional Well-Being of Women Oncologists During the COVID-19 Pandemic: Responding for Tomorrow.| | View in PubMed
- Grade Progression and Intrapatient Tumor Heterogeneity as Potential Contributors to Resistance in Gastroenteropancreatic Neuroendocrine Tumors.| | View in PubMed
- Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.| | View in PubMed
- Preclinical Models of Adrenocortical Cancer.| | View in PubMed
- Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.| | View in PubMed
- Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.| | View in PubMed
- Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review.| | View in PubMed
- Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis.| | View in PubMed
- Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.| | View in PubMed
- Preclinical Models of Neuroendocrine Neoplasia.| | View in PubMed
- DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.| | View in PubMed
- A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.| | View in PubMed
- Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung.| | View in PubMed
- Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?| | View in PubMed
- Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists.| | View in PubMed
- Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.| | View in PubMed
- Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips.| | View in PubMed
- Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study.| | View in PubMed
- Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.| | View in PubMed
- Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.| | View in PubMed
- Outcomes after high-dose radiation in the management of neuroendocrine neoplasms.| | View in PubMed
- The Immunotherapy Landscape in Adrenocortical Cancer.| | View in PubMed
- Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.| | View in PubMed
- Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database.| | View in PubMed
- Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.| | View in PubMed
- Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.| | View in PubMed
- Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis.| | View in PubMed
- Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms.| | View in PubMed
- Carcinoid Crisis-Induced Acute Systolic Heart Failure.| | View in PubMed
- New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.| | View in PubMed
- The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors.| | View in PubMed
- Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of| | View in PubMed
- North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19.| | View in PubMed
- Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?| | View in PubMed
- Reply to S. Boutayeb et al.| | View in PubMed
- Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors.| | View in PubMed
- Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk.| | View in PubMed
- Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.| | View in PubMed
- A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.| | View in PubMed
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.| | View in PubMed
- A Rare Case of Carcinoid Constrictive Pericarditis.| | View in PubMed
- Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.| | View in PubMed
- Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma.| | View in PubMed
- Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.| | View in PubMed
- Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome.| | View in PubMed
- Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.| | View in PubMed
- Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors.| | View in PubMed
- High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.| | View in PubMed
- Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.| | View in PubMed
- Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases.| | View in PubMed
- Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.| | View in PubMed
- Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.| | View in PubMed
- Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.| | View in PubMed
- Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.| | View in PubMed
- Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors.| | View in PubMed
- A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.| | View in PubMed
- Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.| | View in PubMed
- Progress in the Evaluation and Treatment of Small Bowel Neuroendocrine Tumors.| | View in PubMed
- NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.| | View in PubMed
- Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.| | View in PubMed
- Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.| | View in PubMed
- Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.| | View in PubMed
- Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series.| | View in PubMed
- The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.| | View in PubMed
- The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.| | View in PubMed
- A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases.| | View in PubMed
- Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.| | View in PubMed
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.| | View in PubMed
- Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1.| | View in PubMed
- Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.| | View in PubMed
- Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.| | View in PubMed
- Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.| | View in PubMed
- A phase II study of axitinib in advanced neuroendocrine tumors.| | View in PubMed
- KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.| | View in PubMed
- Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.| | View in PubMed
- First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.| | View in PubMed
- Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging.| | View in PubMed
- Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.| | View in PubMed
- A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.| | View in PubMed
- Transcatheter pulmonic valve replacement in carcinoid heart disease.| | View in PubMed
- Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.| | View in PubMed
- Combined mammalian target of rapamycin and vascular endothelial growth factor pathway inhibition in pancreatic neuroendocrine tumors: more than the sum of its parts?| | View in PubMed
- Is more not better?: combination therapies in colorectal cancer treatment.| | View in PubMed
- Neuroendocrine tumors, version 1.2015.| | View in PubMed
- The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.| | View in PubMed
- Bone metastases and skeletal-related events from neuroendocrine tumors.| | View in PubMed
- Neuroendocrine tumors of unknown primary: is the primary site really not known?| | View in PubMed
- Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.| | View in PubMed
- B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.| | View in PubMed
- 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.| | View in PubMed
- Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial.| | View in PubMed
- A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.| | View in PubMed
- Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.| | View in PubMed
- Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.| | View in PubMed
- Introduction: recent advances in the genetics, diagnosis, and treatment of neuroendocrine tumors.| | View in PubMed
- The evolving landscape of neuroendocrine tumors.| | View in PubMed
- Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.| | View in PubMed
- Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.| | View in PubMed
- Neuroendocrine tumors.| | View in PubMed
- Systemic therapy for advanced carcinoid tumors: where do we go from here?| | View in PubMed
- Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.| | View in PubMed
- Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial.| | View in PubMed
- Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.| | View in PubMed
- Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.| | View in PubMed
- Identification of unknown primary tumors in patients with neuroendocrine liver metastases.| | View in PubMed
- The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.| | View in PubMed
- A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.| | View in PubMed
- Glycemic control in patients with insulinoma treated with everolimus.| | View in PubMed
- Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.| | View in PubMed
- Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.| | View in PubMed
- Activity of sunitinib in patients with advanced neuroendocrine tumors.| | View in PubMed
- A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?| | View in PubMed
- Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.| | View in PubMed
- Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.| | View in PubMed
- Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.| | View in PubMed
- Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.| | View in PubMed
- Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?| | View in PubMed
- Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region.| | View in PubMed
- A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.| | View in PubMed
- Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.| | View in PubMed
- Pancreatoblastoma in an adult: case report and review of the literature.| | View in PubMed
- Targeting growth factors and angiogenesis; using small molecules in malignancy.| | View in PubMed
- When does the presence of the target predict response to the targeted agent?| | View in PubMed
- Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.| | View in PubMed
- Anti-angiogenic strategies in gastrointestinal malignancies.| | View in PubMed
- Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.| | View in PubMed
- Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.| | View in PubMed
- Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer.| | View in PubMed
- Update on clinical trials targeting vascular endothelial growth factor in cancer.| | View in PubMed
- Vascular endothelial growth factor as a therapeutic target in cancer.| | View in PubMed
- Angiogenesis in colorectal cancer: therapeutic implications and future directions.| | View in PubMed
- Maximizing the potential of bevacizumab in cancer treatment.| | View in PubMed
- Couples therapy at end of life.| | View in PubMed
- Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.| | View in PubMed
- Immune enhancement of skin carcinogenesis by CD4+ T cells.| | View in PubMed
- Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.| | View in PubMed
- Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature.| | View in PubMed
- Shedding old paradigms: developing viruses to treat cancer.| | View in PubMed
- Molecular mechanisms underlying the development of hepatocellular carcinoma.| | View in PubMed
- Hepatocellular carcinoma.| | View in PubMed
- Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.| | View in PubMed
- Human acellular dermal matrix as a novel model of malignant epithelial cell invasion.| | View in PubMed